Shannon Smiley, MD
Hematology & Oncology · Anchorage, AKNPI 1891715942
Payments from drug & device makers
What this record shows
This record is dominated by consulting fees: $4,950 of the $6,186 with a category attached, or 80.0%. 23 manufacturers reported payments, led by CSL Behring at 44.9% of the total. Reporting peaked in 2022 at $3,923 and has fallen 83.4% since, to $651 in 2025.
Across 54 payments — averaging $114.55 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- CSL Behring$3K
- National Marrow Donor Program$2K
- Johnson & Johnson$199
- Novartis$155
- GSK$115
- Genentech USA, Inc.$105
- plus $662 from 17 others
What the payments were for
- Consulting fees$4,95080%
- Food & beverage$1,03717%
- Education$1993%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| CSL Behring | 6 | $2,775 |
| National Marrow Donor Program | 4 | $2,175 |
| Johnson & Johnson | 2 | $199 |
| Novartis | 7 | $155 |
| GSK | 5 | $115 |
| Genentech USA, Inc. | 4 | $105 |
| AbbVie | 4 | $105 |
| Pfizer | 4 | $93 |
| Mckesson Specialty Care Distribution, LLC | 1 | $66 |
| Acrotech Biopharma Inc. | 2 | $45 |
| Merck | 2 | $41 |
| Array Biopharma Inc | 2 | $38 |
| Ipsen Biopharmaceuticals, Inc | 1 | $32 |
| Stemline Therapeutics Inc. | 1 | $31 |
| Astellas Pharma US Inc | 1 | $30 |
| E.r. Squibb & Sons, L.L.C. | 1 | $27 |
| Springworks Therapeutics, Inc. | 1 | $26 |
| AstraZeneca | 1 | $25 |
| Beone Medicines USA, Inc. | 1 | $24 |
| Pharmacyclics LLC, An Abbvie Company | 1 | $24 |
| Gilead | 1 | $23 |
| EMD Serono, Inc. | 1 | $17 |
| Sanofi | 1 | $15 |
How this compares
Too few hematology & oncology providers in Alaskato place this figure against a meaningful peer group, so we don't.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| CalquenceAcalabrutinib Maleate | 32 | $481,005 |
| TagrissoOsimertinib Mesylate | 17 | $415,433 |
| Lenalidomide | 20 | $306,556 |
| ImbruvicaIbrutinib | 16 | $286,790 |
| JakafiRuxolitinib Phosphate | 16 | $272,931 |
| LumakrasSotorasib | 13 | $268,698 |
| PomalystPomalidomide | 11 | $253,997 |
| RevlimidLenalidomide | 11 | $215,008 |
| EliquisApixaban | 18 | $16,721 |
| XareltoRivaroxaban | 16 | $13,183 |
| Acyclovir | 62 | $1,587 |
| Anastrozole | 36 | $1,222 |
| Levothyroxine Sodium | 12 | $1,206 |
| Hydrocodone-AcetaminophenHydrocodone/Acetaminophen | 39 | $698 |
| Gabapentin | 27 | $649 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AstraZenecaCalquence, Tagrisso | $25 | $896,43849 claims |
| Pharmacyclics LLC, An Abbvie CompanyImbruvica | $24 | $286,79016 claims |
| E.r. Squibb & Sons, L.L.C.Pomalyst | $27 | $253,99711 claims |
| PfizerEliquis | $93 | $16,72118 claims |
| Johnson & JohnsonXarelto | $199 | $13,18316 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. There are too few hematology & oncology providers in Alaskaon file to place this against a meaningful peer group, so we don't.
Other hematology & oncology in Anchorage
- Steven LiuAnchorage$35K
- Max RabinowitzAnchorage$14K
- Mary KlixAnchorage$13K
- Mary StewartAnchorage$9K
- Kendal WebbAnchorage$8K
- Natalie WallaceAnchorage$8K
- Charles BuessAnchorage$5K
- Anusiyanthan MariampillaiAnchorage$4K
- Theodore KimAnchorage$2K
- Ellen ChirichellaAnchorage$1K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.